Vyome Holdings (HIND) Research & Development (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Research & Development of $666405.0 for Q1 2026, up 638.25% year-over-year from $90268.0 in Q1 2025, and up 76.18% quarter-over-quarter from $378252.0 in Q4 2025.
Vyome Holdings (HIND) Research & Development (2015 - 2026) Analysis & Trends
Vyome Holdings' Research & Development history runs 12 years deep, the most recent figure standing at $666405.0 for Q1 2026.
- In Q1 2026, Research & Development rose 638.25% year-over-year to $666405.0; the TTM figure through Mar 2026 stood at $1.7 million (up 86.38% YoY), while the FY2025 annual figure was $588258.0, up 106.12% from the prior year.
- Research & Development for Q1 2026 stood at $666405.0, up from $378252.0 in the prior quarter.
- The five-year high for Research & Development was $747000.0 in Q2 2022, with the low at $39677.0 in Q3 2025.
- The 5-year median for Research & Development is $542000.0 (2023), against an average of $464584.9.
- The sharpest annual moves came in 2024 and 2026: Research & Development tumbled 90.86% in 2024, then soared 638.25% in 2026.
- Vyome Holdings' Research & Development stood at $462000.0 in 2022, then jumped by 59.96% to $739000.0 in 2023, then sank by 90.86% to $67527.0 in 2024, then jumped by 460.15% to $378252.0 in 2025, then surged by 76.18% to $666405.0 in 2026.
- Business Quant data shows HIND's Research & Development at $666405.0 in Q1 2026, $378252.0 in Q4 2025, and $39677.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 506,723.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 506,723.00 |
| Mar 31, 2026 | 666,405.00 |
| Dec 31, 2025 | 378,252.00 |
| Sep 30, 2025 | 39,677.00 |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 90,268.00 |
| Dec 31, 2024 | 67,527.00 |
| Sep 30, 2024 | 66,815.00 |
| Jun 30, 2024 | 670,000.00 |
| Mar 31, 2024 | 484,000.00 |
| Dec 31, 2023 | 739,000.00 |
| Sep 30, 2023 | 542,000.00 |
| Jun 30, 2023 | 581,000.00 |
| Mar 31, 2023 | 453,000.00 |
| Dec 31, 2022 | 462,000.00 |
| Sep 30, 2022 | 583,000.00 |
| Jun 30, 2022 | 747,000.00 |
| Mar 31, 2022 | 745,000.00 |
| Dec 31, 2021 | 270,000.00 |
| Sep 30, 2021 | 1.43 Mn |